Compare GOOS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | PHAR |
|---|---|---|
| Founded | 1957 | 1988 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 885.7M |
| IPO Year | 2016 | 2020 |
| Metric | GOOS | PHAR |
|---|---|---|
| Price | $9.61 | $13.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.60 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 622.5K | 6.8K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | $10.04 |
| Revenue Next Year | $5.16 | $2.51 |
| P/E Ratio | ★ $75.22 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $9.54 |
| 52 Week High | $15.43 | $21.34 |
| Indicator | GOOS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 53.16 |
| Support Level | $9.46 | $12.98 |
| Resistance Level | $10.42 | $13.61 |
| Average True Range (ATR) | 0.33 | 0.44 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 35.11 | 88.43 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.